Predictive Factors of Long-term Survivor (LTS) of Patients With Recurrent or Metastatic, Radio-iodine Resistant Differentiated Thyroid Cancer (RRDTC) After Lenvatinib: a Multicenter Study (PFL)

Patients with recurrent or metastatic, radio-iodine resistant differentiated thyroid cancer (RRDTC) treated with Lenvatinib

Inclusion Criteria:

• Adult patients (≥ 18 years of age)
• Patients capable of providing informed consent
• Patients with a diagnosis of differentiated thyroid carcinoma confirmed by cytological or histological examination, showing disease progression within the last 12 months
• Patients with radioiodine-refractory differentiated thyroid carcinoma (i.e., patients with one or more metastatic lesions without RAI uptake; patients with progressive lesions lacking RAI uptake within the last 12 months; or patients who have received a cumulative RAI dose > 600 mCi)
• ECOG performance status of 0-2
• Patients who are treatment-naïve or with disease recurrence following first-line therapy
• Patients with blood pressure ≤ 150/90 mmHg and adequate bone marrow, liver, and renal function (creatinine clearance > 30 mL/min calculated using the Cockcroft-Gault formula)

Exclusion Criteria:

• Patients with medullary or anaplastic thyroid carcinoma
• Patients with impaired renal function or proteinuria (urinary protein >1 g/24 h)
• Patients with a positive medical history of congestive heart failure, unstable angina, ischemic heart disease, ischemic stroke, or cardiac arrhythmias in the last 6 months
• Patients with a prolonged QT interval on pre-treatment ECG
• Patients previously treated with Lenvatinib